leveraging its strength in the evolving field of quantitative systems pharmacology (QSP). QSP determines
the mechanisms of disease progression and drug reactions through iterative and integrated experimental
and computational methods.
Our current QSP-driven programs are in metastatic cancer, neurodegenerative diseases (including
traumatic brain injury), hepatocarcinoma, and non-alcoholic fatty liver disease. We are launching programs
in other therapeutic areas jointly proposed by teams of clinical, computational, and experimental
investigators to ensure the targeted problems and their solutions are clinically important, practical, and
If you share our vision of developing more effective approaches for healthcare and would like to donate to a specific program or disease area, please visit the Pittsburgh Revolution Fund website to learn more. https://www.pghrevfund.pitt.edu/
Thank you for your interest in our new vision of drug discovery.
D. Lansing Taylor, Director
Connor Wege, Administrator